

7th November 2022

ASX ANNOUNCEMENT

ASX: RSH

ASX Market Announcements Platform
Sydney NSW

RESPIRI ANNOUNCES FIRST PATIENTS ENROLLED INTO WHEEZO[®] REMOTE PATIENT MONITORING PROGRAMS, FURTHER VALIDATING USA BUSINESS MODEL

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce the enrolment of the first patients into the wheezo[®] Remote Patient Monitoring (RPM) program.

Although not financially material, this event marks a key milestone in the execution of the Company USA business strategy. Further, it is anticipated that the RPM Current Procedural Terminology (CPT) reimbursement codes for the wheezo[®] RPM program for such patients will be processed and reimbursed by Centers of Medicare and Medicaid Services (CMS) and other insurers within 45 days, making the wheezo[®] device the first by an Australian MedTech company to be used for monetary reimbursement; another key event. Respiri anticipates the recently announced major customers Children’s Hospital of Michigan and the Healthcare Organisation based in North Carolina to commence onboarding patients on the wheezo[®] program in the coming month, further validating the Company USA business strategy.

The wheezo[®] device is uniquely positioned in the large and growing US respiratory disorders RPM market as it provides an easy to use, reproducible and validated wheeze monitoring solution that qualifies for the RPM CPT reimbursement codes enabling doctors to provide and be paid for these services to patients that are widely regarded as key to reducing complications, exacerbations, attacks, hospitalizations and ultimately deaths. These positive health outcomes aim to reduce healthcare costs which is a key driver for all healthcare stakeholders including physicians, hospitals and insurer/payors.

In the US market physicians are not only directly reimbursed for providing RPM services but can, under their supervision, outsource the implementation of these services to third party providers, such as Access Telehealth, a Respiri partner. These US-centric market dynamics help mitigate many obstacles in providing RPM services to patients, which are experienced in other parts of the world, Australia included.

CEO and Managing Director of Respiri, Mr Marjan Mikel said; “The enrolment of our first patients into the wheezo[®] RPM program is significant as it confirms physician’s acceptance of our technology and program as an important component of managing patients with asthma whilst ensuing reimbursement claims in the next month or so further validate our business strategy and model. We are also excited at our other major customers’ interest around including wheezo[®] into the care of their patients. We are now well into the US

commercialization phase and expect to scale these programs and launch many more with other US-based Healthcare Organisations over the coming quarters, again supporting our chosen US business pathway.”

These significant business milestones are results of the effective and rapid execution of our US business strategy developed by Respi management. The partners’ sales pipeline and progress with these interested potential customers remains very encouraging and the Company anticipates announcing more healthcare organisations adopting wheezo® RPM programs for their patients and for existing customers to continue to grow the number of patients that they enroll into their existing wheezo® RPM programs.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respi Limited
P: +61 408 462 873
E: marjan@respi.co

Mr Nicholas Smedley
Executive Chairman
Respi Limited
P: +61 447 074 160
E: nicholas@respi.co

This ASX announcement has been authorised for release by the Board of Directors of Respi Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com> wheezo® is a registered trademark of Respi Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.